Logo image of PACS

PACS GROUP INC (PACS) Stock Fundamental Analysis

NYSE:PACS - US69380Q1076 - Common Stock

11.86 USD
+0.2 (+1.72%)
Last: 8/27/2025, 8:10:54 PM
11.86 USD
0 (0%)
After Hours: 8/27/2025, 8:10:54 PM
Fundamental Rating

3

Overall PACS gets a fundamental rating of 3 out of 10. We evaluated PACS against 101 industry peers in the Health Care Providers & Services industry. PACS has a bad profitability rating. Also its financial health evaluation is rather negative. PACS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year PACS was profitable.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.90%, PACS is in the better half of the industry, outperforming 63.37% of the companies in the same industry.
Looking at the Return On Equity, with a value of 19.73%, PACS belongs to the top of the industry, outperforming 87.13% of the companies in the same industry.
PACS's Return On Invested Capital of 4.38% is in line compared to the rest of the industry. PACS outperforms 53.47% of its industry peers.
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROIC 4.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 50 100 150 200

1.3 Margins

Looking at the Profit Margin, with a value of 3.63%, PACS is in the better half of the industry, outperforming 70.30% of the companies in the same industry.
PACS has a better Operating Margin (6.68%) than 66.34% of its industry peers.
PACS has a Gross Margin (21.33%) which is in line with its industry peers.
Industry RankSector Rank
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

PACS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PACS has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, PACS has a worse debt to assets ratio.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 50M 100M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.44, we must say that PACS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.44, PACS is not doing good in the industry: 62.38% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.90 indicates that PACS is somewhat dependend on debt financing.
PACS has a Debt to Equity ratio of 0.90. This is in the lower half of the industry: PACS underperforms 60.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 1.44
ROIC/WACC0.52
WACC8.49%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

PACS has a Current Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
PACS's Current ratio of 1.71 is in line compared to the rest of the industry. PACS outperforms 59.41% of its industry peers.
PACS has a Quick Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.71, PACS is in the better half of the industry, outperforming 63.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

PACS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
Looking at the last year, PACS shows a very strong growth in Revenue. The Revenue has grown by 28.47%.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%

3.2 Future

The Earnings Per Share is expected to grow by 37.45% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 18.92% on average over the next years. This is quite good.
EPS Next Y92.3%
EPS Next 2Y46.69%
EPS Next 3Y37.45%
EPS Next 5YN/A
Revenue Next Year28.62%
Revenue Next 2Y22.64%
Revenue Next 3Y18.92%
Revenue Next 5YN/A

3.3 Evolution

PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B 5B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.5 1 1.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 15.61 indicates a correct valuation of PACS.
Based on the Price/Earnings ratio, PACS is valued cheaply inside the industry as 80.20% of the companies are valued more expensively.
PACS is valuated rather cheaply when we compare the Price/Earnings ratio to 27.14, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 7.22 indicates a rather cheap valuation of PACS.
Based on the Price/Forward Earnings ratio, PACS is valued cheaper than 96.04% of the companies in the same industry.
PACS is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.61
Fwd PE 7.22
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

PACS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. PACS is cheaper than 69.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.72
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

PACS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PACS's earnings are expected to grow with 37.45% in the coming years.
PEG (NY)0.17
PEG (5Y)N/A
EPS Next 2Y46.69%
EPS Next 3Y37.45%

More info and screens

0

5. Dividend

5.1 Amount

PACS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACS GROUP INC

NYSE:PACS (8/27/2025, 8:10:54 PM)

After market: 11.86 0 (0%)

11.86

+0.2 (+1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners29.43%
Inst Owner Change0.03%
Ins Owners71.98%
Ins Owner Change-0.49%
Market Cap1.84B
Analysts82
Price Target33.66 (183.81%)
Short Float %5.68%
Short Ratio4.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.28%
Min EPS beat(2)24.18%
Max EPS beat(2)56.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.83%
Min Revenue beat(2)2.62%
Max Revenue beat(2)5.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.07%
PT rev (3m)-7.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.41%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE 15.61
Fwd PE 7.22
P/S 0.59
P/FCF N/A
P/OCF N/A
P/B 3.22
P/tB 3.63
EV/EBITDA 9.72
EPS(TTM)0.76
EY6.41%
EPS(NY)1.64
Fwd EY13.86%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS20.05
BVpS3.69
TBVpS3.27
PEG (NY)0.17
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROCE 6.06%
ROIC 4.38%
ROICexc 4.47%
ROICexgc 4.56%
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA 2.21
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z 1.44
F-ScoreN/A
WACC8.49%
ROIC/WACC0.52
Cap/Depr(3y)671.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
EPS Next Y92.3%
EPS Next 2Y46.69%
EPS Next 3Y37.45%
EPS Next 5YN/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
Revenue Next Year28.62%
Revenue Next 2Y22.64%
Revenue Next 3Y18.92%
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.13%
EBIT Next 3Y32.1%
EBIT Next 5YN/A
FCF growth 1Y-74.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.22%
OCF growth 3YN/A
OCF growth 5YN/A